Table 2.
Mutation analysis of BCR-ABL1 kinase domain mutations in PAX5-transduced CML cells
| Cell Type | CD19+ clones | AID mRNA [% COX6B] | ABL1 exons 4-6 Sequence analysis | Clones | Amino acid change | IC50 [μmol/l Imatinib] |
|---|---|---|---|---|---|---|
| KYO-GFP | < 0.01% | <0.01 | 764 GAG→AAG | 1/35 | E255K | 12.1 |
| Wildtype and silent | 34/35 | 0.6 | ||||
| Imatinib-resistant | 1/35 (2.9%) | |||||
| KYO-PAX5/GFP | ~0.5% | 4.24 ± 0.95 | 742 CTG→GTG | 4/48 | L248V | 7.0 |
| 764 GAG→AAG | 5/48 | E255K | 12.1 | |||
| 944 ACT→ATT | 16/48 | T315I | 16 | |||
| 1078 ATC→GTC | 2/48 | I360V | unknown | |||
| 1187 CAT→CGT | 2/48 | H396R | 1.8 | |||
| Wildtype and silent | 21/48 | 0.6 | ||||
| Imatinib-resistant | 27/48 (56%) | |||||